Tuesday, January 07, 2003 11:31:38 AM
International BioChemical Industries Announces That It Has Signed a 'Master Distribution Agreement' With Nova BioGenetics, Inc.
Friday December 27, 2:22 pm ET
ATLANTA, Dec. 27 /PRNewswire-FirstCall/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL - News) announced today that it signed a master distribution agreement with its joint partner Nova BioGenetics, Inc. IBCI has entered into this agreement to strengthen its capability for marketing of its products. IBCI will continue to provide R&D technical support to Nova as well as production of products, while maintaining a stronger profit margin due to reduction in overhead.
The company believes this approach will strengthen sales into the market and develop a stronger pipeline. Under this agreement Nova will undertake all sales efforts for IBCI products, technical sales support and marketing programs. Nova has demonstrated they're capable of bringing strong distribution connections to the technology and the ability to move forward on sales agreements. Nova's financial commitment to marketing IBCI's products will give IBCI the required strength to move the products forward with the appropriate marketing and staff.
About: International BioChemical Industries
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is an alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria on contact and can remain active for extended time periods. To date IBCI has received four U.S. patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.
Further information on IBCI and its line of products can be found by visiting the firm's web site at http://www.bioshield.com , or by calling 1-770-925-3653, Tim Moses.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
The best weapon against "fear" is "facts"!!
Friday December 27, 2:22 pm ET
ATLANTA, Dec. 27 /PRNewswire-FirstCall/ -- International BioChemical Industries, Inc. (OTC Bulletin Board: IBCL - News) announced today that it signed a master distribution agreement with its joint partner Nova BioGenetics, Inc. IBCI has entered into this agreement to strengthen its capability for marketing of its products. IBCI will continue to provide R&D technical support to Nova as well as production of products, while maintaining a stronger profit margin due to reduction in overhead.
The company believes this approach will strengthen sales into the market and develop a stronger pipeline. Under this agreement Nova will undertake all sales efforts for IBCI products, technical sales support and marketing programs. Nova has demonstrated they're capable of bringing strong distribution connections to the technology and the ability to move forward on sales agreements. Nova's financial commitment to marketing IBCI's products will give IBCI the required strength to move the products forward with the appropriate marketing and staff.
About: International BioChemical Industries
International BioChemical Industries, Inc. is a Norcross, Georgia-based emerging growth company focused in biotechnology and antimicrobial products. Its core business is committed to the discovery, development, marketing and sale of surface-modifying antimicrobial and biostatic products. The company's antimicrobial technology is an alternative to conventional sanitizers, disinfectants, bleaches, biocides or preservatives primarily because it kills bacteria on contact and can remain active for extended time periods. To date IBCI has received four U.S. patents and eight EPA registrations, including the first U.S. germ killer and disinfectant against Salmonella cholerasuis, Staphylococcus aureus and other microorganisms. The company has developed several alliances in different industries, such as healthcare, textiles and storm water.
Further information on IBCI and its line of products can be found by visiting the firm's web site at http://www.bioshield.com , or by calling 1-770-925-3653, Tim Moses.
Safe Harbor/Forward-looking Statements:
Statements in this news release that are not historical are forward- looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in any forward-looking statements, all of which are difficult to predict and many of which are beyond the control of the company, including areas such as: developing technologies; dependence on collaborative partners; the inherent complexity and uncertainty regarding the development of products; early-stage development of IBCI; the result of research and development efforts; future capital needs; uncertainty of additional funding; government regulations; and other factors which are detailed in the company's periodic reports and registration statements filed with the Securities and Exchange Commission. IBCI does not undertake to revise or update any forward- looking statement to reflect events or circumstances that may arise after the date hereof. BioShield is a trademark of IBCI.
The best weapon against "fear" is "facts"!!
The best weapon against "fear" is "facts"!!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
